Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets

Abstract

The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design. The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications. Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clinical utility due to their propensity to incite on-target adverse events. Chemically distinct classes of cannabinergic ligands exhibit signaling bias at CBRs toward individual subsets of signal transduction pathways. In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists. We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses. The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs.

Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor

“…The Cnr2 receptor is a single peptide seven-transmembrane domain receptor that belongs to the family of G protein-coupled receptors (GPR). Cnr2 contains an extracellular glycosilated Nterminus and an internal C-terminus domain that is coupled to a Gi/o protein ( Figure 2) [17,50,51]. Cnr2 activation negatively regulates adenylyl cyclase activity [52], causing a reduction of intracellular level of cyclic adenosine monophosphate [53,54], that in turn leads to the modulation of an array of signalling pathways ( Figure 2 adhesion molecules like ICAM or VCAM, matrix metalloproteinases, focal adhesion kinase (FAK) and small GTP binding proteins RhoA ( Figure 2).…”

Cannabichromene is a cannabinoid CB2 receptor agonist

“…Cannabinoid receptors mediate downstream signalling predominantly through the G i/o protein family (Mallipeddi, et al, 2017), but CB 1 can couple G s -proteins when there is no functional G i/o -coupling (Bonhaus et al, 1998;Glass & Felder, 1997), and affect G q in some environments (Lauckner, Hille, & Mackie, 2005). The loss of CBC signalling upon PTX treatment confirms G i/o -protein coupling in the hyperpolarization assay, consistent with previous findings with these cells (Banister et al, 2016).…”

Bioligands Acting on the Cannabinoid Receptor CB1 for the Treatment of Withdrawal Syndrome Caused by Cannabis sativa

“…The CB1 receptor is a subfamily member of the G protein-coupled receptors (GPCRs) [28] and is predominantly present in the presynaptic terminal, although small amounts are present in peripheral nerves and its function seems to modulate the release of neurotransmitters such as dopamine, noradrenaline, glutamate, and serotonin in the synaptic cleft [29].…”